Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company's lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. It also develops Rexista Oxycodone, an abuse and alcohol-deterrent controlled-release oral formulation for the relief of pain; Regabatin XR and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; and Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease. In addition, the company offers Glucophage XR, an oral antihyperglycemia drug to treat type 2 diabetes; Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder. Further, it provides Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
http://www.priceseries.com/trade/IPCI-Intellipharmaceutics-International-Inc-stock-gains-767-percent-a-Trade-Record-by-priceSeries-2018090620181001.html
